MS clinical trials: Lessons from recent failures

International MS Journal

Volumn 8, Issue 3, 2001, Pages 96-102

  Zajicek, John ^a   Fox, Patrick ^a  

^a DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CELL ADHESION MOLECULE; GLATIRAMER; IMMUNOGLOBULIN G1; LENERCEPT; PLACEBO; PROTEIN P55; ROQUINIMEX; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTHRALGIA; CELL ACTIVATION; CLINICAL FEATURE; CLINICAL TRIAL; CORRELATION ANALYSIS; CYTOKINE RELEASE; DISABILITY; DISEASE COURSE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EXPERIMENTAL MODEL; HUMAN; MULTIPLE SCLEROSIS; MYALGIA; NATURAL KILLER CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; OUTCOMES RESEARCH; PERICARDITIS; RATING SCALE; REVIEW; TREATMENT FAILURE;

EID: 0035710069     PISSN: 13528963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives
2. New insight into disease mechanisms in multiple sclerosis
3. The ups and downs of multiple sclerosis therapeutics
4. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: Do cytokines trigger off exacerbations?
5. Tumour necrosis factor mediates myelin and oligodendrocyte damage in vitro
6. Interactions between oligodendrocytes and microglia. A major role for complement and tumour necrosis factor in oligodendrocyte adherence and killing
7. Death inducing functions of ligands of the tumour necrosis factor family
8. Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumour necrosis factor receptor 1
9. TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study
10. Exacerbations of multiple sclerosis in patients treated with gamma interferon
11. Stimulation of NK cell, T cell and monocyte functions by the novel immunomodulator Linomide after autologous bone marrow transplantation. A pilot study in patients with acute myeloid leukaemia
12. Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide
13. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: A double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation
14. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis
15. Roquinimex (linomide) treatment in secondary progressive and relapsing remitting multiple sclerosis: Results from 48 week randomized double-blind placebo-controlled pilot studies
16. Linomide in relapsing and secondary progressive MS: Part I: Trial design and clinical results
17. In vitro immunomodulatory effects of sulfasalazine and its metabolites
18. Suppression of experimental autoimmune encephalomyelitis by sulphasalazine
19. The Mayo Clinic-Canadian cooperative trial of sulfasalazine in active multiple sclerosis
20. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
21. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
22. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial